The stomach medication that became the biggest blockbuster of the 1990s

The omeprazole molecule was synthesised as early as 1979, but it took many years before the then Astra had an approved pharmaceutical. Once this happened, a tab...

Biosimilars bring price pressure, but are they sufficiently used?

When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely e...

RFK Jr: I september vet vi vad som orsakar autism

USA ska identifiera orsaken till autism – och det ska vara gjort till september i år. Det säger USA:s hälsominister Robert F. Kennedy Jr., som därmed sätter en ...

KI-forskare har upptäckt biomarkörer för postcovid

Forskare vid Karolinska institutet har i en ny studie identifierat en uppsättning proteiner i blod hos personer med långvariga besvär av postcovid.

New study: Post-Covid symptoms are common even after mild Covid-19

According to researchers at the University of Gothenburg, loss of smell and taste, shortness of breath and chest symptoms are the most common complaints after a...

Vinnova is going to establish a new innovation cluster

Vinnova, the Swedish Agency for Innovation Systems, has been commissioned by the government to establish a national innovation cluster for advanced medicines.

RegFile AB

Brexit looking back and looking forward

More than 3 years have passed after the vote and there is still uncertainty around the outcome although the UK December 12 election set a clearer course towards...

Rising interest in CRISPR treatments

Treatments using CRISPR technology are emerging as one of the hottest medical trends in the United States – and the FDA is doing its best to promote the development.

Ossiform: Quality control of 3D printed bone implants

Ossiform chose the GOM Scan 1.

Drug development creates new challenges for regulators

Giulia Gaudenzi: ”Key lessons from global health research”

The world will still face major challenges in the post Covid-19 pandemic, writes Giulia Gaudenzi at the KTH Division of Nanobiotechnology at Scilifelab, in a column.

Novavax is developing a vaccine candidate against Covid-19 and seasonal flu

A combined vaccine against both Covid-19 and seasonal flu is showing promising results in studies, according to the American drug developer Novavax. The adjuvan...

Now it’s settled: The International Vaccine Institute will be located in Stockholm

The International Vaccine Institute, IVI, is establishing itself outside South Korea for the first time. Last week, the Swedish Parliament ratified the agreemen...

Björn Arvidsson: “We need robust and recognized ecosystems for continued competitiveness”

“We have idea carriers and excellent innovation opportunities, and now we must invest in creating ecosystems that provide them with even better growth opportuni...

Study: Our behaviour may have been guided by wishful thinking during the pandemic

A new study suggests that we systematically underestimate health risks if and when it suits us. This was especially true during the pandemic, as our risk assess...

Pfizer’s record year – topped the $100 billion mark

In 2022 Pfizer, as the first pharmaceutical company in history, reached an annual revenue of more than 100 billion dollars, thereby surpassing Johnson & Johnson...

Unexpected study results on testosterone – no reduction in fracture risk

Testosterone treatment is known to increase bone density and bone quality. However, a study now suggests that supplementation with the male sex hormone does not...

The Swedish Research Council gets go-ahead for more long-term funding

Following a government decision, the Swedish Research Council will soon be able to approve ten-year grant periods for funding research infrastructure, which may...

Column: "Are we already living in the new normal?"

2020 felt like the year that we were building the house around us whilst moving into it at the same time.

Kompauto Nordic AB

Immedica högt på listan över Sveriges bästa arbetsplatser

Stockholmsbaserade Immedica Pharma hamnar tvåa på listan över Sveriges bästa arbetsplatser i kategorin medelstora organisationer. Även andra läkemedelsföretag f...

“Everyone is screaming for talent”

Attracting talent is one of the life science industry’s major future challenges, which was one of the conclusions of the panel discussion that ended the New Hor...

IVI’s Director General on establishing in Sweden: Will need up to 40 employees

The International Vaccine Institute, IVI, hopes to have its first staff on-site in Stockholm within a couple of months, says the institute’s Director General Je...